Key result
In patients treated with nilotinib, new electrocardiographic abnormalities were recorded in 20% and clinical cardiac adverse events in 9%, while significant QT prolongation and changes in left ventricular ejection fraction were uncommon.
Why the study?
Does nilotinib cause significant cardiac adverse events, QT prolongation, or LVEF changes in patients with chronic myeloid leukemia?
Cohort (n=81)
No
Does nilotinib cause significant cardiac adverse events, QT prolongation, or LVEF changes in patients with chronic myeloid leukemia?
In patients treated with nilotinib, significant QT prolongation and LVEF reduction were uncommon, though clinical cardiac events occurred in 9% of patients, primarily those with prior cardiovascular risk factors.
No takes yet. Share an insight, caveat, or question.
Nilotinib warrants cardiac monitoring in CML patients with prior risks; leaves open causal inference without randomized data.
Kim et al. (2012) conducted a cohort in Chronic myeloid leukemia (n=81). Nilotinib was evaluated on Cardiac safety profile (QT interval, left ventricular ejection fraction, and clinical cardiac adverse events). In patients treated with nilotinib, new electrocardiographic abnormalities were recorded in 20% and clinical cardiac adverse events in 9%, while significant QT prolongation and changes in left ventricular ejection fraction were uncommon.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: